Lv1
20 积分 2024-11-27 加入
Pediatric glioblastoma in the setting of constitutional mismatch‐repair deficiency treated with upfront lomustine and nivolumab
1天前
待确认
TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants
5个月前
已完结
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
6个月前
已完结
皖公网安备34019202002308
